Atlas Trials

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer

Clinical trial NCT06798506 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06798506
Sponsor
Fudan University
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
TNBC - Triple-Negative Breast Cancer
Start date
2025-02-15
Primary completion
2027-01-15
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.